What is the standard dosing protocol for Sermorelin?

Conventional Sermorelin dosing is 200-500 mcg 1x daily subq (evening) via subq. For female hormonal and cyclical use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

What is the regulatory status of Sermorelin?

Sermorelin regulatory status: Approval withdrawn 2008 (commercial reasons); compounded prescription use widespread in the United States; WADA status banned (s2); research level research level investigational. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For female hormonal and cyclical use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

What is the evidence base for Sermorelin?

Sermorelin's evidence base sits at research level investigational. The references on this page summarise 2 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The female physiology interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

What does Sermorelin stack well with?

For female physiology protocols, Sermorelin pairs with compounds on complementary pathways: Oxytocin, Kisspeptin, GHK-Cu. These pairings are selected because they engage independent receptor systems from Sermorelin's primary mechanism (GHRH receptor agonist on pituitary somatotrophs), producing additive or synergistic effects rather than receptor competition.

Is Sermorelin safe during pregnancy or breastfeeding?

Sermorelin, like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

Home/ Compounds/ Sermorelin

Sermorelin

Women's Health

Cycle-aware, fertility-aware, perimenopause-aware: Sermorelin is evaluated by women's-health clinicians on multiple axes. GHRH receptor agonist on pituitary somatotrophs Stimulates endogenous GH release while preserving the natural pulsatile pattern and negative feedback regulation, which lowers the risk of receptor desensitisation compared to exogenous GH.. The compound's truncated ghrh analogue pharmacology produces measurable effects on the systems women's-health practice cares about — cycle regularity, mood, bone density, cardiovascular tone, and the perimenopausal transition. Each is examined in the sections below.

Female Physiology Applications

MenopauseCardiovascular (Female)Autoimmune SupportVaginal HealthEndometriosis Support

Key Takeaways

Female-physiology lens: Sermorelin response varies across follicular and luteal phases for premenopausal users; integrates with HRT in perimenopause and postmenopause.
Mechanism: GHRH receptor agonist on pituitary somatotrophs.
Female monitoring: cycle-day-appropriate estradiol, progesterone, FSH, LH, prolactin, TSH, bone markers; pregnancy contraindication is default.
Female dose: 200-500 mcg 1x daily subq (evening) via subq; cycle-phase tracking for 1-2 cycles.
Female-physiology stack partners: Oxytocin, Kisspeptin, GHK-Cu.

Female Physiology Mechanism

GHRH receptor agonist on pituitary somatotrophs. Stimulates endogenous GH release while preserving the natural pulsatile pattern and negative feedback regulation, which lowers the risk of receptor desensitisation compared to exogenous GH. Female-physiology implications operate across three life-stage contexts: pre-menopausal cyclical users, the perimenopausal transition, and post-menopausal users on or off HRT. Sermorelin's response varies meaningfully across these contexts, as the subsections on cyclical context, perimenopause integration, fertility, and bone-and-cardiovascular signalling describe.

Perimenopause and menopause integration

For women in the perimenopausal or post-menopausal window, Sermorelin is most effective when integrated with the broader hormonal picture — HRT (estrogen, progesterone, sometimes testosterone), bone-density support, and cardiometabolic monitoring. Many compounds in this category produce stronger effects in this window precisely because the surrounding hormonal landscape is changing.

Bone density and cardiovascular signalling

Two areas where female physiology diverges sharply post-menopause are bone remodelling and cardiovascular tone. Sermorelin's effect on these systems is one of the underweighted but practically important considerations for women using peptides through the menopausal transition. Bone-marker labs (CTX, P1NP) and cardiovascular indices (lipids, blood pressure, hsCRP) provide a tractable monitoring framework.

Fertility and reproductive considerations

Sermorelin's effect on fertility-relevant endpoints — ovulation, ovarian reserve markers, uterine receptivity, lactation — deserves explicit consideration for women in the reproductive window. Most well-studied compounds have minimal direct effect on reproductive endpoints at therapeutic doses, but pregnancy and active conception remain explicit contraindications for most non-approved peptides.

Female Physiology Applications

Endometriosis Support

For endometriosis support in female users, Sermorelin is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.

Bone Density

Bone Density is one of the dimensions on which women track Sermorelin response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.

Menopause

In the perimenopausal window, Sermorelin for menopause produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.

Body Composition (Female)

For body composition (female) in female users, Sermorelin is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	200-500 mcg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	120-500 mcg	4–6 weeks initial cycle
Women's Health focus	SubQ	200-500 mcg	1x daily SubQ (evening)
Maintenance phase	SubQ	140-500 mcg	Ongoing with periodic pauses

Dose timing for Sermorelin is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.

Stacking

Sermorelin stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from women's-health clinicians.

Sermorelin + Oxytocin: Activates oxytocin receptors (OXTR) peripherally (uterine smooth muscle, mammary alveoli) and centrally (amygdala, hypothalamus, ventral tegmentum). Pairs naturally with Sermorelin's mechanism in female physiology protocols.
Sermorelin + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with Sermorelin's mechanism in female physiology protocols.
Sermorelin + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with Sermorelin's mechanism in female physiology protocols.
Sermorelin + Epithalon: Identified by Khavinson in St. Pairs naturally with Sermorelin's mechanism in female physiology protocols.

Safety & Regulatory Status

WADA: Banned (S2) FDA: Approval withdrawn 2008 (commercial reasons); compounded prescription use widespread

Site reactions occasional. Headache, flushing possible. Long pulsatile use generally safer than exogenous GH.

Lens-specific safety considerations for female physiology use of Sermorelin: Site reactions occasional. Headache, flushing possible. Long pulsatile use generally safer than exogenous GH. Additional female physiology monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Sermorelin — GHRH (1-29) in clinical use

PMID 3525289

Supporting

Sermorelin pediatric GH deficiency

PMID 8754682

Sermorelin vs Related Peptides

Compound	Profile	Onset	Best For
Sermorelin	Truncated GHRH analogue	~10-20 min	Women's Health
Oxytocin	Posterior pituitary nonapeptide	~1-6 min plasma; CNS longer	The 'bonding hormone' — a posterior pituitary nonapeptide with effects on uterine contraction, lactation, and a wide range of social and sexual behaviour via central oxytocin receptors
Kisspeptin	Hypothalamic upstream regulator of GnRH	~28 min IV	The upstream master regulator of GnRH neurons — driving the entire HPG axis from above
PT-141	Melanocortin receptor agonist	~2-3 hr	An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women

Frequently Asked Questions

Best monitoring labs for female users?

Baseline panel: estradiol (cycle-day-appropriate), progesterone, FSH, LH, prolactin, TSH free T3 free T4, fasting glucose, HbA1c, lipids, CBC, CMP, hsCRP, vitamin D, ferritin. Follow-up at 6–8 weeks. For perimenopausal users add bone markers (CTX, P1NP) and cardiovascular indices.

Can I use Sermorelin during pregnancy or while trying to conceive?

Most peptide therapeutics, including Sermorelin, do not have safety data supporting use during pregnancy or active conception. The default position is to discontinue at least 2–3 cycles before planned conception and to avoid throughout pregnancy and lactation unless specifically approved by a physician familiar with the indication.

Will Sermorelin affect contraceptive efficacy?

For most peptide compounds, contraceptive efficacy is not significantly affected. Compounds directly modulating the HPG axis (kisspeptin, gonadorelin) are exceptions and warrant alternative or additional contraceptive measures during use. Sermorelin's specific interaction follows its mechanism.

Is Sermorelin appropriate during perimenopause?

Yes, and many women report stronger response in the perimenopausal window than at younger ages. The interaction with HRT — estrogen, progesterone, sometimes testosterone — is generally additive rather than competitive. Bone density, cardiovascular, and metabolic monitoring continues to apply.

What is Sermorelin?

Sermorelin (also known as Geref / GHRH(1-29)) is a 29-residue truncated ghrh analogue with a molecular weight of 3358 Da and a plasma half-life of ~10-20 min. GHRH receptor agonist on pituitary somatotrophs. Stimulates endogenous GH release while preserving the natural pulsatile pattern and negative feedback regulation, which lowers the risk of receptor desensitisation compared to exogenous GH. The compound is studied primarily in the female physiology domain for the applications outlined above.

Should I cycle Sermorelin?

Standard cycle for Sermorelin is 8–12 weeks of 1x daily subq (evening) 200-500 mcg dosing via subq, followed by a 4 week complete off-period. The off-period is calibrated to Sermorelin's ~10-20 min half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

Clinical Protocol

Start a Sermorelin Protocol

Alukard provides physician-supervised women's health protocols with GMP-certified Sermorelin and Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get Protocol

Quick Facts

Molecular weight: 3358 Da
Sequence length: 29 aa
Half-life: ~10-20 min
WADA: Banned (S2)
FDA: Approval withdrawn 2008 (commercial reasons); compounded prescription use widespread

Stack Partners

Oxytocin

Kisspeptin

GHK-Cu

Epithalon

PT-141

Research Note

All female physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Sermorelin unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised women's health protocols

Start Your Female Physiology Protocol for Sermorelin

Alukard provides physician-supervised women's health protocols with Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised